Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Self-Collected versus Healthcare Worker-Collected Swabs in the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Value of 68Ga-PSMA PET/CT Following Equivocal 18F-NaF PET/CT in Prostate Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Varicocele Testis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Contemporary Thoughts on the Role of Shockwave Therapy in Peyronie's Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Early detection of prostate cancer (PC) is paramount as localized disease is generally curable, while metastatic PC is generally incurable. There is a need for improved, minimally invasive biomarkers as current diagnostic tools are inaccurate, leading to extensive overtreatment while still missing some clinically significant cancers. Consequently, we profiled the expression levels of 92 selected microRNAs by RT-qPCR in plasma samples from 753 patients, representing multiple stages of PC and non-cancer controls. First, we compared plasma miRNA levels in patients with benign prostatic hyperplasia (BPH) or localized prostate cancer (LPC), versus advanced prostate cancer (APC). We identified several dysregulated microRNAs with a large overlap of 59 up/down-regulated microRNAs between BPH versus APC and LPC versus APC. Besides identifying several novel PC-associated dysregulated microRNAs in plasma, we confirmed the previously reported upregulation of miR-375 and downregulation of miR-146a-5p. Next, by randomly splitting our dataset into a training and test set, we identified and successfully validated a novel four microRNA diagnostic ratio model, termed bCaP (miR-375*miR-33a-5p/miR-16-5p*miR-409-3p). Combined in a model with prostate specific antigen (PSA), digital rectal examination status, and age, bCaP predicted the outcomes of transrectal ultrasound (TRUS)-guided biopsies (negative vs. positive) with greater accuracy than PSA alone (Training: area under the curve (AUC), model = 0.84; AUC, PSA = 0.63. Test set: AUC, model = 0.67; AUC, PSA = 0.56). It may be possible in the future to use this simple and minimally invasive bCaP test in combination with existing clinical parameters for a more accurate selection of patients for prostate biopsy.

OriginalsprogEngelsk
TidsskriftDiagnostics
Vol/bind10
Udgave nummer4
ISSN2075-4418
DOI
StatusUdgivet - 28 mar. 2020

ID: 60068947